financetom
Business
financetom
/
Business
/
Update: Market Chatter: EU Set to Delay Basel Bank Trading Rules by 1 Year
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Market Chatter: EU Set to Delay Basel Bank Trading Rules by 1 Year
Jun 11, 2024 9:44 AM

12:02 PM EDT, 06/11/2024 (MT Newswires) -- (Updates with additional details and European Commission spokesperson response in the third and fourth paragraph.)

The European Union is poised to delay the implementation of rules that impact banks' trading businesses by one year since those activities are global in nature and the bloc's lenders would be disadvantaged by the ongoing wrangling over standards in the US, Bloomberg reported Tuesday, citing people familiar with the matter.

The European Commission has the authority to delay rules on banks' trading operations without consulting with the European Parliament or governments, the report said.

A Commission spokesperson told MT Newswires in an emailed response that the Basel III standards are being finalized for implementation by Jan. 1, 2025, and that the Commission will support EU banks and stakeholders in this process.

"Given the uncertainty around the implementation of the standards in other jurisdictions, the Commission monitors the international developments and stands ready to act if necessary in specific areas," the spokesperson said.

"The exercise of this power would not delay the implementation of all new Basel rules, but only the rules on market risk," Bloomberg quoted a European Commission spokesperson as saying.

There has been no formal decision yet regarding a partial delay, but the EU may introduce new Basel rules by this summer, Bloomberg said, citing the sources.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 15.86, Change: -0.57, Percent Change: -3.47

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved